{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:04:46Z","timestamp":1744862686915,"version":"3.40.4"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Corticosteroids are active in castration\u2010resistant prostate cancer (CRPC) by suppression of adrenal androgen production. Triamcinolone is an intramuscular steroid injection which has putative advantages over commonly used steroids, such as dexamethasone and prednisolone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicentre, phase II study of intramuscular triamcinolone administered monthly in patients with chemotherapy\u2010na\u00efve CRPC. 55 patients were recruited from 2012 to 2016. Imaging was performed every 3 months. The primary end point was radiological and symptomatic progression\u2010free survival (PFS). Secondary end points included PSA progression, weight changes, and toxicity. We also conducted an exploratory analysis on steroid androgenic precursors, collected before and 1 month after triamcinolone, to measure correlation to PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At a median follow\u2010up time of 18.7 months, the median radiological PFS was 9.4 months (95% confidence interval [CI]: 7.4\u201320.3 months), and the 6\u2010month radiological PFS rate was 69.1% (95% CI: 55.1%\u201379.5%). The 50% PSA response rate was 63.6% (95% CI: 49.6\u201376.2). There were no treatment\u2010related deaths. The most common grade 3 toxicity was hypertension (44%), but only five patients (9%) required concomitant medication. Proximal myopathy was observed in 22 patients (40%). There was no evidence of weight gain (mean weight 83.5\u2009kg pre\u2010study and 79.8\u2009kg post\u2010study). Urinary total androgen metabolites and dehydroepiandrosterone did not predict response to triamcinolone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Intramuscular triamcinolone is an effective hormonal agent in CRPC. Its side\u2010effect profile is different from other steroids and has the advantage of supervised administration.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.24877","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T05:19:57Z","timestamp":1742361597000},"page":"703-709","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate\u2010Resistant Prostate Cancer (TRICREST)"],"prefix":"10.1002","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-4075","authenticated-orcid":false,"given":"Kenrick","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology St Bartholomew's Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garima","family":"Priyadarshini","sequence":"additional","affiliation":[{"name":"Centre for Experimental Cancer Medicine Queen Mary University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0254-432X","authenticated-orcid":false,"given":"Shah\u2010Jalal","family":"Sarker","sequence":"additional","affiliation":[{"name":"Centre for Experimental Cancer Medicine Queen Mary University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angus","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Oncology University Hospitals Sussex NHS Foundation Trust Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"McPhail","sequence":"additional","affiliation":[{"name":"Department of Oncology Raigmore Hospital Inverness Scotland UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Prendergrast","sequence":"additional","affiliation":[{"name":"Centre for Experimental Cancer Medicine Queen Mary University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Ackermann","sequence":"additional","affiliation":[{"name":"Centre for Experimental Cancer Medicine Queen Mary University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernese","family":"Xhafa\u2010Hamiti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew's Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Greenwood","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew's Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry King's College Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Drake","sequence":"additional","affiliation":[{"name":"Department of Endocrinology St Bartholomew's Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew's Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00119-z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.220200"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.061"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.5.590"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.004"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds216"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.143.5.8778"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.11.004"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"issue":"11","key":"e_1_2_10_16_1","first-page":"E727","article-title":"Diethylstilbestrol in Castration\u2010Resistant Prostate Cancer","volume":"110","author":"Wilkins A.","year":"2012","journal-title":"BJU International"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07583.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-018-1394-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1961"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1341"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02473.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1819"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T06:03:24Z","timestamp":1744783404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/pros.24877"],"URL":"https:\/\/doi.org\/10.1002\/pros.24877","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"type":"print","value":"0270-4137"},{"type":"electronic","value":"1097-0045"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"2024-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}